Journal article
Genetic Variants Related to Longer Telomere Length are Associated with Increased Risk of Renal Cell Carcinoma
MJ Machiela, JN Hofmann, R Carreras-Torres, KM Brown, M Johansson, Z Wang, M Foll, P Li, N Rothman, SA Savage, V Gaborieau, JD McKay, Y Ye, M Henrion, F Bruinsma, S Jordan, G Severi, K Hveem, LJ Vatten, T Fletcher Show all
European Urology | ELSEVIER | Published : 2017
Abstract
Background Relative telomere length in peripheral blood leukocytes has been evaluated as a potential biomarker for renal cell carcinoma (RCC) risk in several studies, with conflicting findings. Objective We performed an analysis of genetic variants associated with leukocyte telomere length to assess the relationship between telomere length and RCC risk using Mendelian randomization, an approach unaffected by biases from temporal variability and reverse causation that might have affected earlier investigations. Design, setting, and participants Genotypes from nine telomere length-associated variants for 10 784 cases and 20 406 cancer-free controls from six genome-wide association studies (GWA..
View full abstractGrants
Awarded by National Cancer Institute
Funding Acknowledgements
US Department of Health and Human Services, US National Institute of Health, US National Cancer Institute, American Cancer Society, Duncan Family Institute for Cancer Prevention and Risk Assessment, Masaryk Memorial Cancer Institute were involved in the design and conduct of the study, collection of the data, and approval of the manuscript. This study was funded by support from the following institutions: Intramural research program of the National Cancer Institute, American Cancer Society, Masaryk Memorial Cancer Institute (MMCI) in Brno was supported by MH CZ - DRO (MMCI, 00209805). MD Anderson study GWAS was supported in part by the NIH (grant R01 CA170298) and the Center for Translational and Public Health Genomics, Duncan Family Institute for Cancer Prevention and Risk Assessment, The University of Texas MD Anderson Cancer Center. The WHI programis funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, US Department of Health and Human Services through contracts HHSN268201600018C, HHSN268201600001C, HHSN268201600002C, HHSN268201600003C, and HHSN268201600004C.